ArticleClinical ophthalmology (Auckland, N.Z.)2026
Real-World Treatment Patterns and Clinical Outcomes with Cyclosporine 0.1% in Semifluorinated Alkane for Dry Eye Disease.
Article in Clinical ophthalmology (Auckland, N.Z.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To evaluate real-world clinical outcomes and treatment patterns associated with long-term use of cyclosporine 0.1% in semifluorinated alkane (SFA) (VEVYE Methods: This retrospective, real-world evidence, observational study analyzed electronic medical records from 55 patients with DED treated with cyclosporine 0.1% in SFA (CsA/SFA) for at least six months. Patient-reported symptoms were assessed using the Standard Patient Evaluation of Eye Dryness (SPEED) questionnaire. Corneal fluorescein staining was evaluated using the Oxford grading scale. All outcomes were compared from baseline to the most recent follow-up visit using paired statistical tests, with a two-sided p-value of less than 0.05 considered statistically significant. Results: The cohort comprised 48 female and 7 male patients. Mean SPEED scores decreased from 12.53 ± 7.17 to 8.36 ± 5.77, representing a clinically and statistically relevant 33.2% reduction (p < 0.001). Mean Oxford staining scores demonstrated clinically and statistically relevant decreases from 1.11 ± 0.83 to 0.49 ± 0.54 in the right eye (55.7% reduction; p < 0.001) and from 1.14 ± 0.84 to 0.59 ± 0.65 in the left eye (48.0% reduction; p < 0.001). Conclusion: CsA/SFA was associated with clinically and statistically significant improvements in both patient-reported symptoms and corneal staining over six months, with concordant improvements in subjective and objective outcome measures. These findings support its use as an effective therapeutic option for moderate DED.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.